Autologous Bone-Marrow-Derived-Mononuclear-Cells-Enriched Fat Transplantation in Breast Augmentation: Evaluation of Clinical Outcomes and Aesthetic Results in a 30-Year-Old Female

Autologous fat transfer (lipofilling) is becoming an invaluable tool for breast augmentation as well as for breast reconstruction. Autologous lipofilling has several advantages, including biocompatibility, versatility, natural appearance, and low donor site morbidity. The main limitation is unpredictable fat graft resorption, which ranges from 25% to 80%, probably as a result of ischaemia and lack of neoangiogenesis. To obviate these disadvantages, several studies have searched for new ways of increasing the viability of the transplanted fat tissue. One promising approach is to enrich the fat graft with autologous bone-marrow-derived mononuclear cells (BMMNCs) before transplantation. BMMNCs produce many angiogenic and antiapoptotic growth factors, and their secretion is significantly enhanced by hypoxia. All of these mechanisms of actions could be beneficial for the stimulation of angiogenesis in ischemic tissues by BMMNCs administration. In our aesthetic surgery practice, we use fat transplantation enriched with BMMNCs, which caused a significant improvement in survival of fat grafts, compared with that of traditional lipofilling. Our experience with freshly isolated autologous fat enriched with BMMNCs for breast augmentation procedures is presented. The concept of this surgical and tissue handling technique is based on ability of BMMNCs to stimulate blood vessel growth.

Download Full-text

Treatment of Adult Severe Traumatic Brain Injury Using Autologous Bone Marrow Mononuclear Cells

10.21236/ada570264 ◽

2012 ◽

Cited By ~ 1

Author(s):

Charles Cox

Keyword(s):

Traumatic Brain Injury ◽

Bone Marrow ◽

Brain Injury ◽

Severe Traumatic Brain Injury ◽

Mononuclear Cells ◽

Autologous Bone Marrow ◽

Bone Marrow Mononuclear Cells ◽

Autologous Bone

Download Full-text

Autologous Bone Marrow-Derived Mononuclear Cells Combined With β-TCP for Maxillary Bone Augmentation in Implantation Procedures

Journal of Craniofacial Surgery ◽

10.1097/scs.0000000000000326 ◽

2017 ◽

Vol 28 (8) ◽

pp. 1982-1987 ◽

Cited By ~ 1

Author(s):

Dmitry Bulgin ◽

Enes Hodzic

Keyword(s):

Bone Marrow ◽

Mononuclear Cells ◽

Autologous Bone Marrow ◽

Bone Augmentation ◽

Maxillary Bone ◽

Autologous Bone

Download Full-text

Administration of Autologous Bone Marrow-Derived Mononuclear Cells in Children with Incurable Neurological Disorders and Injury is Safe and Improves their Quality of Life

Cell Transplantation ◽

10.3727/096368912x633798 ◽

2012 ◽

Vol 21 (1_suppl) ◽

pp. 79-90 ◽

Cited By ~ 37

Author(s):

Alok Sharma ◽

Nandini Gokulchandran ◽

Guneet Chopra ◽

Pooja Kulkarni ◽

Mamta Lohia ◽

...

Keyword(s):

Quality Of Life ◽

Bone Marrow ◽

Neurological Disorders ◽

Mononuclear Cells ◽

Autologous Bone Marrow ◽

Autologous Bone

Download Full-text

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

Blood ◽

10.1182/blood.v80.7.1666.bloodjournal8071666 ◽

1992 ◽

Vol 80 (7) ◽

pp. 1666-1672

Author(s):

S Jagannath ◽

DH Vesole ◽

L Glenn ◽

J Crowley ◽

B Barlogie

Keyword(s):

Bone Marrow ◽

Stem Cell ◽

Mononuclear Cells ◽

Intensive Therapy ◽

Autologous Bone Marrow ◽

Blood Stem Cell ◽

High Dose ◽

Platelet Recovery ◽

Gm Csf ◽

Autologous Bone

To improve the safety of autotransplantation for myeloma, peripheral blood stem cell (PBSC) collection was attempted in 75 previously treated patients after the administration of high-dose cyclophosphamide (HD-CTX; 6 g/m2) with or without granulocyte-macrophage colony- stimulating factor (GM-CSF). Sixty patients subsequently received melphalan 200 mg/m2 (57 patients) or melphalan 140 mg/m2 and total body irradiation (850 cGy) (3 patients) supported by both autologous bone marrow and PBSC; 38 patients received GM-CSF posttransplantation. Among 72 patients undergoing PBSC apheresis, “good” mobilization (greater than 50 colony-forming units granulocyte-macrophage [CFU-GM] per 10(5) mononuclear cells) was achieved when prior chemotherapy did not exceed 1 year and when GM-CSF was used post-HD-CTX; similarly, rapid platelet recovery to 50,000/microL within 2 weeks was associated with “good” PBSC mobilization. These same variables also predicted for rapid engraftment after autotransplantation, so that hematologic recovery (granulocytes greater than 500/microL and platelets greater than 50,000/microL) proceeded within 2 weeks among the 37 patients with “good” PBSC collection. As a result of rapid neutrophil recovery (greater than 500/microL) within a median of 2 weeks, infectious complications both post-HD-CTX and posttransplant were readily manageable, resulting in only one treatment-related death post-HD-CTX. The cumulative response rate (greater than or equal to 75% cytoreduction) for all 75 patients was 68%, with 12-month event-free and overall survival projections of about 85%. Using both bone marrow and PBSC together with GM-CSF, autotransplants are safe and appear effective in myeloma, especially when prior therapy had been limited to less than 1 year. More than 80% of transplanted patients achieved complete hematologic recovery within a median of 1 month posttransplant (granulocytes greater than 1,500/microL; platelets greater than 100,000/microL; hemoglobin greater than 10 g%), thus providing sufficient hematopoietic reserve for further chemotherapy in the event of posttransplant relapse.

Download Full-text